 Kiang-Teck Jerry Yeo
Concepts (349)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunoassay | 11 | 2022 | 94 | 2.910 |
Why?
| | Clinical Chemistry Tests | 4 | 2019 | 12 | 2.060 |
Why?
| | Antibodies, Viral | 4 | 2022 | 345 | 1.850 |
Why?
| | Immunoglobulin M | 4 | 2021 | 172 | 1.340 |
Why?
| | Pre-Eclampsia | 5 | 2022 | 235 | 1.200 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 4 | 2022 | 92 | 1.080 |
Why?
| | Pharmacogenetics | 9 | 2022 | 413 | 1.080 |
Why?
| | Automation, Laboratory | 2 | 2020 | 11 | 1.050 |
Why?
| | Peptide Fragments | 6 | 2011 | 482 | 1.010 |
Why?
| | Natriuretic Peptide, Brain | 5 | 2011 | 70 | 0.940 |
Why?
| | Thyroid Function Tests | 1 | 2022 | 114 | 0.930 |
Why?
| | Serologic Tests | 1 | 2020 | 45 | 0.850 |
Why?
| | Blood Specimen Collection | 2 | 2012 | 35 | 0.850 |
Why?
| | Triiodothyronine | 1 | 2022 | 320 | 0.820 |
Why?
| | Hyperkalemia | 2 | 2012 | 45 | 0.820 |
Why?
| | Endothelial Growth Factors | 10 | 1996 | 60 | 0.780 |
Why?
| | Lymphokines | 10 | 1996 | 115 | 0.780 |
Why?
| | Vitamin B 12 | 1 | 2018 | 19 | 0.730 |
Why?
| | Hyperparathyroidism, Primary | 1 | 2019 | 53 | 0.730 |
Why?
| | Smith-Lemli-Opitz Syndrome | 1 | 2018 | 2 | 0.730 |
Why?
| | Parathyroidectomy | 1 | 2019 | 99 | 0.720 |
Why?
| | Parathyroid Hormone | 1 | 2019 | 238 | 0.690 |
Why?
| | Drug Monitoring | 1 | 2018 | 121 | 0.680 |
Why?
| | Hypogonadism | 1 | 2017 | 38 | 0.680 |
Why?
| | Humans | 67 | 2022 | 84199 | 0.670 |
Why?
| | Testosterone | 2 | 2017 | 286 | 0.660 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 41 | 0.640 |
Why?
| | Proteomics | 1 | 2018 | 194 | 0.640 |
Why?
| | Developmental Disabilities | 1 | 2018 | 190 | 0.630 |
Why?
| | Cytochrome P-450 CYP2D6 | 5 | 2022 | 53 | 0.620 |
Why?
| | Cholesterol | 1 | 2018 | 438 | 0.600 |
Why?
| | Chorionic Gonadotropin | 2 | 2014 | 68 | 0.600 |
Why?
| | Fibromyalgia | 1 | 2015 | 13 | 0.600 |
Why?
| | Immunoglobulin G | 4 | 2021 | 483 | 0.600 |
Why?
| | Sensitivity and Specificity | 6 | 2022 | 2082 | 0.570 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2014 | 48 | 0.550 |
Why?
| | Analgesics | 1 | 2015 | 125 | 0.540 |
Why?
| | Myocardial Ischemia | 2 | 2005 | 173 | 0.510 |
Why?
| | Chronic Pain | 1 | 2015 | 113 | 0.510 |
Why?
| | Genotype | 7 | 2022 | 1858 | 0.510 |
Why?
| | Carcinoma, Papillary | 1 | 2014 | 183 | 0.490 |
Why?
| | Reagent Kits, Diagnostic | 4 | 2020 | 41 | 0.490 |
Why?
| | Tacrolimus | 1 | 2014 | 385 | 0.470 |
Why?
| | Reproducibility of Results | 7 | 2021 | 2685 | 0.460 |
Why?
| | Troponin I | 3 | 2003 | 28 | 0.460 |
Why?
| | Diagnostic Errors | 1 | 2012 | 169 | 0.430 |
Why?
| | Potassium | 1 | 2012 | 308 | 0.430 |
Why?
| | Genotyping Techniques | 1 | 2011 | 65 | 0.430 |
Why?
| | Nerve Tissue Proteins | 2 | 2004 | 530 | 0.430 |
Why?
| | Legislation, Medical | 1 | 2010 | 9 | 0.420 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 99 | 0.420 |
Why?
| | Artifacts | 1 | 2012 | 249 | 0.410 |
Why?
| | Warfarin | 2 | 2019 | 109 | 0.410 |
Why?
| | Antibodies, Heterophile | 2 | 2000 | 20 | 0.400 |
Why?
| | Thyroid Neoplasms | 1 | 2014 | 440 | 0.400 |
Why?
| | Anticoagulants | 3 | 2019 | 403 | 0.390 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2021 | 2346 | 0.380 |
Why?
| | Chromatography, Liquid | 2 | 2019 | 104 | 0.370 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 1028 | 0.350 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 1194 | 0.350 |
Why?
| | False Positive Reactions | 4 | 2020 | 227 | 0.340 |
Why?
| | Pregnancy | 7 | 2022 | 2849 | 0.340 |
Why?
| | Hemolysis | 2 | 2020 | 65 | 0.330 |
Why?
| | Limit of Detection | 2 | 2018 | 19 | 0.320 |
Why?
| | Female | 22 | 2022 | 45032 | 0.310 |
Why?
| | Rifampin | 1 | 2006 | 20 | 0.310 |
Why?
| | Oxycodone | 1 | 2006 | 29 | 0.300 |
Why?
| | Protein Precursors | 2 | 2011 | 148 | 0.300 |
Why?
| | Exercise | 2 | 2005 | 283 | 0.290 |
Why?
| | Cardiolipins | 1 | 2002 | 18 | 0.250 |
Why?
| | Erythrocyte Transfusion | 2 | 2013 | 56 | 0.250 |
Why?
| | Predictive Value of Tests | 4 | 2018 | 1774 | 0.240 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2005 | 306 | 0.240 |
Why?
| | Erythrocytes | 2 | 2013 | 269 | 0.230 |
Why?
| | Pain Management | 2 | 2021 | 132 | 0.230 |
Why?
| | Travel Medicine | 1 | 2021 | 1 | 0.230 |
Why?
| | Autoantibodies | 1 | 2002 | 261 | 0.220 |
Why?
| | Cross Reactions | 1 | 2021 | 135 | 0.220 |
Why?
| | Fetal Growth Retardation | 1 | 2021 | 76 | 0.220 |
Why?
| | Infant, Newborn | 4 | 2022 | 2457 | 0.210 |
Why?
| | Jaundice | 1 | 2020 | 15 | 0.210 |
Why?
| | Blood Proteins | 1 | 2001 | 160 | 0.210 |
Why?
| | Equipment Design | 2 | 2021 | 424 | 0.210 |
Why?
| | Hepatitis B Antibodies | 1 | 2020 | 17 | 0.210 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 81 | 0.210 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2020 | 27 | 0.210 |
Why?
| | Indicators and Reagents | 1 | 2000 | 79 | 0.210 |
Why?
| | Liver | 1 | 2006 | 1260 | 0.210 |
Why?
| | Thyroid Gland | 1 | 2022 | 289 | 0.210 |
Why?
| | Platelet Function Tests | 1 | 2019 | 10 | 0.210 |
Why?
| | Blood Chemical Analysis | 1 | 2000 | 49 | 0.200 |
Why?
| | Genomics | 2 | 2019 | 657 | 0.200 |
Why?
| | Hyperglycemia | 2 | 2001 | 184 | 0.200 |
Why?
| | Mixed Function Oxygenases | 2 | 2010 | 66 | 0.200 |
Why?
| | Middle Aged | 14 | 2021 | 25702 | 0.200 |
Why?
| | Vascular Endothelial Growth Factors | 10 | 1996 | 62 | 0.200 |
Why?
| | Adult | 17 | 2021 | 26137 | 0.200 |
Why?
| | Glycoproteins | 1 | 2001 | 253 | 0.200 |
Why?
| | Hyperlipidemias | 1 | 2020 | 133 | 0.200 |
Why?
| | Peripartum Period | 1 | 2019 | 18 | 0.190 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2019 | 27 | 0.190 |
Why?
| | Intraoperative Period | 1 | 2019 | 103 | 0.190 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 51 | 0.190 |
Why?
| | Medication Adherence | 1 | 2020 | 121 | 0.180 |
Why?
| | Decision Support Techniques | 1 | 2020 | 162 | 0.180 |
Why?
| | Dehydrocholesterols | 1 | 2018 | 2 | 0.180 |
Why?
| | Biological Availability | 1 | 2018 | 105 | 0.180 |
Why?
| | Decision Support Systems, Clinical | 1 | 2019 | 115 | 0.180 |
Why?
| | Serotonin | 1 | 2019 | 241 | 0.180 |
Why?
| | Male | 15 | 2021 | 42140 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 10 | 1996 | 385 | 0.170 |
Why?
| | Perioperative Care | 1 | 2019 | 165 | 0.170 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 324 | 0.170 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 52 | 0.170 |
Why?
| | Anesthesiology | 1 | 2019 | 164 | 0.170 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 381 | 0.160 |
Why?
| | Vitamin D | 1 | 2019 | 264 | 0.160 |
Why?
| | Myocardium | 1 | 2000 | 555 | 0.160 |
Why?
| | Prognosis | 4 | 2019 | 3729 | 0.160 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 1996 | 6 | 0.160 |
Why?
| | Diabetic Retinopathy | 2 | 1994 | 68 | 0.160 |
Why?
| | Pilot Projects | 2 | 2018 | 838 | 0.160 |
Why?
| | Blood Pressure | 3 | 2019 | 1207 | 0.160 |
Why?
| | Fluoroimmunoassay | 2 | 1994 | 2 | 0.160 |
Why?
| | Autoimmune Diseases | 1 | 2018 | 236 | 0.160 |
Why?
| | Heart Failure | 1 | 2005 | 1114 | 0.150 |
Why?
| | Critical Care | 1 | 2019 | 371 | 0.150 |
Why?
| | Libido | 1 | 2015 | 6 | 0.150 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2001 | 546 | 0.150 |
Why?
| | Gels | 1 | 2015 | 49 | 0.150 |
Why?
| | Case-Control Studies | 4 | 2020 | 1833 | 0.150 |
Why?
| | Health Promotion | 1 | 2017 | 166 | 0.150 |
Why?
| | Quality Control | 2 | 2012 | 127 | 0.140 |
Why?
| | Coronavirus Infections | 1 | 2020 | 289 | 0.140 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 315 | 0.140 |
Why?
| | Vitreous Body | 1 | 1994 | 58 | 0.140 |
Why?
| | Fatigue | 1 | 2015 | 173 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2018 | 696 | 0.140 |
Why?
| | Blood Glucose | 3 | 2017 | 904 | 0.130 |
Why?
| | Calibration | 1 | 2014 | 104 | 0.130 |
Why?
| | Blood Preservation | 1 | 2013 | 10 | 0.130 |
Why?
| | Hemoglobin, Sickle | 1 | 2013 | 17 | 0.130 |
Why?
| | Hyperammonemia | 1 | 2013 | 10 | 0.130 |
Why?
| | Mass Spectrometry | 1 | 2014 | 183 | 0.130 |
Why?
| | Time Factors | 5 | 2012 | 5516 | 0.120 |
Why?
| | Centrifugation | 1 | 2012 | 32 | 0.120 |
Why?
| | Phlebotomy | 1 | 2012 | 21 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2014 | 1611 | 0.120 |
Why?
| | Hypertension | 3 | 2018 | 1215 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 947 | 0.110 |
Why?
| | Anemia, Sickle Cell | 1 | 2013 | 132 | 0.110 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 92 | 0.110 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2001 | 1300 | 0.110 |
Why?
| | Chest Pain | 1 | 2011 | 44 | 0.110 |
Why?
| | African Americans | 1 | 2019 | 1171 | 0.110 |
Why?
| | Smoking | 2 | 2006 | 571 | 0.110 |
Why?
| | Acute Coronary Syndrome | 1 | 2011 | 45 | 0.110 |
Why?
| | Drug Industry | 1 | 2011 | 43 | 0.110 |
Why?
| | Alleles | 2 | 2011 | 1119 | 0.100 |
Why?
| | Drug Therapy | 1 | 2010 | 77 | 0.100 |
Why?
| | Genetic Markers | 1 | 2010 | 493 | 0.100 |
Why?
| | Insulin | 2 | 2006 | 1172 | 0.100 |
Why?
| | Glucuronosyltransferase | 1 | 2010 | 188 | 0.090 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 124 | 0.090 |
Why?
| | Pharmaceutical Preparations | 1 | 2010 | 92 | 0.090 |
Why?
| | Cell Line | 2 | 2011 | 2620 | 0.090 |
Why?
| | Vancomycin | 1 | 1989 | 94 | 0.090 |
Why?
| | Troponin T | 2 | 2011 | 32 | 0.090 |
Why?
| | Neoplasms | 2 | 2021 | 2725 | 0.090 |
Why?
| | Leukocyte Count | 1 | 2008 | 225 | 0.090 |
Why?
| | Prospective Studies | 4 | 2021 | 4122 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2011 | 443 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 927 | 0.080 |
Why?
| | Nanotechnology | 1 | 2007 | 82 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2007 | 214 | 0.080 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2006 | 42 | 0.080 |
Why?
| | Gene Duplication | 1 | 2007 | 129 | 0.080 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2006 | 42 | 0.080 |
Why?
| | Aged | 7 | 2021 | 18611 | 0.080 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2006 | 78 | 0.080 |
Why?
| | Narcotics | 1 | 2006 | 70 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1207 | 0.070 |
Why?
| | Hydrocortisone | 2 | 2004 | 304 | 0.070 |
Why?
| | Molecular Structure | 1 | 2006 | 289 | 0.070 |
Why?
| | Multicenter Studies as Topic | 1 | 2005 | 155 | 0.070 |
Why?
| | Diabetes Mellitus | 2 | 2017 | 764 | 0.070 |
Why?
| | Cohort Studies | 3 | 2019 | 2731 | 0.070 |
Why?
| | Algorithms | 1 | 2013 | 1854 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 706 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2004 | 236 | 0.070 |
Why?
| | Human Growth Hormone | 1 | 2004 | 55 | 0.070 |
Why?
| | Edetic Acid | 1 | 2003 | 46 | 0.070 |
Why?
| | Exercise Test | 1 | 2004 | 175 | 0.070 |
Why?
| | Regression Analysis | 1 | 2005 | 628 | 0.070 |
Why?
| | Ischemia | 1 | 2005 | 250 | 0.060 |
Why?
| | Risk Assessment | 2 | 2022 | 2295 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2006 | 383 | 0.060 |
Why?
| | Adolescent | 3 | 2021 | 9210 | 0.060 |
Why?
| | Nicotine | 1 | 2004 | 170 | 0.060 |
Why?
| | United States | 2 | 2019 | 6396 | 0.060 |
Why?
| | Methylprednisolone | 1 | 2002 | 75 | 0.060 |
Why?
| | Temperature | 1 | 2003 | 424 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2015 | 7966 | 0.060 |
Why?
| | ROC Curve | 1 | 2004 | 764 | 0.060 |
Why?
| | Dibenzothiazepines | 1 | 2001 | 4 | 0.060 |
Why?
| | Risperidone | 1 | 2001 | 24 | 0.060 |
Why?
| | Young Adult | 3 | 2021 | 6007 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 411 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2002 | 158 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2021 | 6605 | 0.060 |
Why?
| | Long QT Syndrome | 1 | 2001 | 37 | 0.050 |
Why?
| | Heart Diseases | 1 | 2003 | 315 | 0.050 |
Why?
| | Phenotype | 1 | 2007 | 2320 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2002 | 216 | 0.050 |
Why?
| | Antipsychotic Agents | 1 | 2001 | 118 | 0.050 |
Why?
| | Evaluation Studies as Topic | 1 | 2000 | 312 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2019 | 7798 | 0.050 |
Why?
| | Binding, Competitive | 1 | 2019 | 176 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2002 | 362 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2002 | 342 | 0.050 |
Why?
| | Drug Prescriptions | 1 | 2020 | 133 | 0.050 |
Why?
| | Morbidity | 1 | 2019 | 147 | 0.050 |
Why?
| | Pain | 1 | 2021 | 364 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2019 | 134 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 417 | 0.040 |
Why?
| | Aortic Aneurysm | 1 | 1998 | 81 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2021 | 991 | 0.040 |
Why?
| | Pain, Postoperative | 1 | 2019 | 238 | 0.040 |
Why?
| | Follicular Fluid | 1 | 1996 | 9 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 274 | 0.040 |
Why?
| | Ascitic Fluid | 1 | 1996 | 39 | 0.040 |
Why?
| | Ovulation Induction | 1 | 1996 | 30 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 1996 | 194 | 0.040 |
Why?
| | Semen | 1 | 1995 | 13 | 0.040 |
Why?
| | Mitogens | 1 | 1995 | 67 | 0.040 |
Why?
| | Cardiopulmonary Bypass | 2 | 2002 | 165 | 0.040 |
Why?
| | Seminal Vesicles | 1 | 1995 | 36 | 0.040 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 1995 | 18 | 0.040 |
Why?
| | Birth Weight | 1 | 1995 | 150 | 0.040 |
Why?
| | Fetal Blood | 1 | 1995 | 98 | 0.040 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1995 | 106 | 0.040 |
Why?
| | DNA, Complementary | 1 | 1996 | 412 | 0.040 |
Why?
| | Protein Binding | 1 | 2019 | 1511 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 3883 | 0.040 |
Why?
| | Pandemics | 1 | 2020 | 559 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 1994 | 56 | 0.040 |
Why?
| | Survival Rate | 1 | 2019 | 1925 | 0.030 |
Why?
| | Infant | 1 | 2021 | 3136 | 0.030 |
Why?
| | Cross-Over Studies | 2 | 2006 | 414 | 0.030 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2013 | 3 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 656 | 0.030 |
Why?
| | Hematocrit | 1 | 2013 | 78 | 0.030 |
Why?
| | Ammonia | 1 | 2013 | 41 | 0.030 |
Why?
| | Chicago | 1 | 2018 | 1455 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 1996 | 356 | 0.030 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 1994 | 161 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2019 | 1784 | 0.030 |
Why?
| | Automation | 1 | 2013 | 116 | 0.030 |
Why?
| | Prostate | 1 | 1995 | 268 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 1995 | 452 | 0.030 |
Why?
| | Microcirculation | 1 | 1992 | 114 | 0.030 |
Why?
| | Fibrin | 1 | 1992 | 83 | 0.030 |
Why?
| | Europium | 1 | 1992 | 3 | 0.030 |
Why?
| | Guinea Pigs | 1 | 1992 | 179 | 0.030 |
Why?
| | Antibody Specificity | 1 | 1992 | 158 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2011 | 26 | 0.030 |
Why?
| | Greece | 1 | 2011 | 19 | 0.030 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2011 | 85 | 0.030 |
Why?
| | Body Weight | 1 | 2013 | 504 | 0.030 |
Why?
| | Psoriasis | 1 | 1994 | 224 | 0.030 |
Why?
| | Animals | 3 | 2005 | 27167 | 0.030 |
Why?
| | Albumins | 1 | 2011 | 120 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 5454 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 1995 | 1452 | 0.030 |
Why?
| | Pathology, Molecular | 1 | 2010 | 32 | 0.030 |
Why?
| | Melanoma | 1 | 1996 | 517 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1994 | 3198 | 0.030 |
Why?
| | Autoanalysis | 1 | 1989 | 6 | 0.030 |
Why?
| | Heart Arrest, Induced | 1 | 1989 | 24 | 0.030 |
Why?
| | Atrial Natriuretic Factor | 1 | 1989 | 39 | 0.030 |
Why?
| | Creatine | 1 | 1989 | 19 | 0.020 |
Why?
| | Obesity | 1 | 2017 | 975 | 0.020 |
Why?
| | Hypothermia, Induced | 1 | 1989 | 72 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 1989 | 332 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2004 | 1912 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1992 | 2178 | 0.020 |
Why?
| | Absorption | 1 | 2006 | 32 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2006 | 43 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 125 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2006 | 180 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2006 | 48 | 0.020 |
Why?
| | Area Under Curve | 1 | 2006 | 345 | 0.020 |
Why?
| | Genome, Human | 1 | 2010 | 760 | 0.020 |
Why?
| | Mass Screening | 1 | 1990 | 626 | 0.020 |
Why?
| | Transforming Growth Factor alpha | 2 | 1995 | 52 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1989 | 2104 | 0.020 |
Why?
| | DNA | 1 | 2010 | 1307 | 0.020 |
Why?
| | Glucose Tolerance Test | 1 | 2004 | 241 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2006 | 391 | 0.020 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2002 | 23 | 0.020 |
Why?
| | Etomidate | 1 | 2002 | 10 | 0.020 |
Why?
| | Reference Values | 1 | 2003 | 704 | 0.010 |
Why?
| | Smoking Cessation | 1 | 2004 | 178 | 0.010 |
Why?
| | Child | 1 | 2013 | 6847 | 0.010 |
Why?
| | Respiratory Mechanics | 1 | 2002 | 106 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2002 | 158 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2002 | 238 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2003 | 378 | 0.010 |
Why?
| | Cells, Cultured | 2 | 1995 | 2974 | 0.010 |
Why?
| | RNA, Messenger | 2 | 1995 | 2008 | 0.010 |
Why?
| | Hemodynamics | 1 | 2002 | 719 | 0.010 |
Why?
| | Gene Expression Regulation | 2 | 1995 | 1960 | 0.010 |
Why?
| | Oligonucleotides, Antisense | 1 | 1996 | 69 | 0.010 |
Why?
| | Erythema Multiforme | 1 | 1995 | 4 | 0.010 |
Why?
| | Dermatitis Herpetiformis | 1 | 1995 | 9 | 0.010 |
Why?
| | Pemphigoid, Bullous | 1 | 1995 | 12 | 0.010 |
Why?
| | Mice, SCID | 1 | 1996 | 241 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 1995 | 104 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1995 | 123 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1995 | 324 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 1994 | 62 | 0.010 |
Why?
| | Keratinocytes | 1 | 1995 | 135 | 0.010 |
Why?
| | Receptors, Immunologic | 1 | 1995 | 165 | 0.010 |
Why?
| | Cell Division | 1 | 1996 | 750 | 0.010 |
Why?
| | Mice, Nude | 1 | 1996 | 787 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1996 | 1088 | 0.010 |
Why?
| | Transfection | 1 | 1996 | 946 | 0.010 |
Why?
| | Fibrinogen | 1 | 1992 | 59 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1995 | 1067 | 0.010 |
Why?
| | Blood Coagulation | 1 | 1992 | 90 | 0.010 |
Why?
| | Binding Sites | 1 | 1995 | 1125 | 0.010 |
Why?
| | Capillary Permeability | 1 | 1992 | 135 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2002 | 2280 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 1996 | 1058 | 0.010 |
Why?
| | Singapore | 1 | 1990 | 19 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1995 | 1830 | 0.010 |
Why?
| | Gene Expression | 1 | 1995 | 1341 | 0.010 |
Why?
| | Base Sequence | 1 | 1994 | 2431 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 1989 | 34 | 0.010 |
Why?
| | Kinetics | 1 | 1992 | 1624 | 0.010 |
Why?
| | Pulmonary Wedge Pressure | 1 | 1989 | 109 | 0.010 |
Why?
| | Heart Valve Prosthesis | 1 | 1989 | 93 | 0.010 |
Why?
| | Heparin | 1 | 1989 | 188 | 0.010 |
Why?
| | Diabetic Nephropathies | 1 | 1990 | 230 | 0.010 |
Why?
| | Mitral Valve | 1 | 1989 | 238 | 0.010 |
Why?
| | Sex Factors | 1 | 1990 | 1095 | 0.010 |
Why?
| | Heart Rate | 1 | 1989 | 564 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 1272 | 0.000 |
Why?
| | Mice | 1 | 1996 | 11210 | 0.000 |
Why?
|
|
Yeo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|